Your browser doesn't support javascript.
loading
Longitudinal Retinal Changes in MOGAD.
Oertel, Frederike Cosima; Sotirchos, Elias S; Zimmermann, Hanna G; Motamedi, Seyedamirhosein; Specovius, Svenja; Asseyer, Eva Susanna; Chien, Claudia; Cook, Lawrence; Vasileiou, Eleni; Filippatou, Angeliki; Calabresi, Peter A; Saidha, Shiv; Pandit, Lekha; D'Cunha, Anitha; Outteryck, Olivier; Zéphir, Hélène; Pittock, Sean; Flanagan, Eoin P; Bhatti, M Tariq; Rommer, Paulus S; Bsteh, Gabriel; Zrzavy, Tobias; Kuempfel, Tania; Aktas, Orhan; Ringelstein, Marius; Albrecht, Philipp; Ayzenberg, Ilya; Pakeerathan, Thivya; Knier, Benjamin; Aly, Lilian; Asgari, Nasrin; Soelberg, Kerstin; Marignier, Romain; Tilikete, Caroline Froment; Cobo Calvo, Alvaro; Villoslada, Pablo; Sanchez-Dalmau, Bernardo; Martinez-Lapiscina, Elena H; Llufriu, Sara; Green, Ari J; Yeaman, Michael R; Smith, Terry J; Brandt, Alexander U; Chen, John; Paul, Friedemann; Havla, Joachim.
Afiliação
  • Oertel FC; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universitätzu Berlin, Berlin, Germany.
  • Sotirchos ES; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Zimmermann HG; Department of Neurology, University of California San Francisco, San Francisco, CA.
  • Motamedi S; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Specovius S; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universitätzu Berlin, Berlin, Germany.
  • Asseyer ES; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Chien C; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universitätzu Berlin, Berlin, Germany.
  • Cook L; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Vasileiou E; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universitätzu Berlin, Berlin, Germany.
  • Filippatou A; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Calabresi PA; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universitätzu Berlin, Berlin, Germany.
  • Saidha S; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Pandit L; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universitätzu Berlin, Berlin, Germany.
  • D'Cunha A; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Outteryck O; Department of Pediatrics, University of Utah, Salt Lake City, UT.
  • Zéphir H; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Pittock S; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Flanagan EP; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Bhatti MT; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Rommer PS; Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, India.
  • Bsteh G; Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, India.
  • Zrzavy T; Department of Neuroradiology, CHU Lille, Université de Lille, Lille, Hauts-de-France, France.
  • Kuempfel T; Department of Neuroradiology, CHU Lille, Université de Lille, Lille, Hauts-de-France, France.
  • Aktas O; Department of Neurology, Mayo Clinic, Rochester, MN.
  • Ringelstein M; Department of Neurology, Mayo Clinic, Rochester, MN.
  • Albrecht P; Department of Neurology, Mayo Clinic, Rochester, MN.
  • Ayzenberg I; Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Pakeerathan T; Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Knier B; Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Aly L; Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universität München, Munich, Germany.
  • Asgari N; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Soelberg K; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Marignier R; Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Tilikete CF; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Cobo Calvo A; Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
  • Villoslada P; Department of Neurology, I.M. Sechenov First Department of Neurology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Sanchez-Dalmau B; Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
  • Martinez-Lapiscina EH; Department of Neurology, I.M. Sechenov First Department of Neurology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Llufriu S; Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
  • Green AJ; Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
  • Yeaman MR; Departments of Neurology, Lillebaelt & Slagelse Hospitals, Denmark.
  • Smith TJ; Institute of Regional Health Research and of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Brandt AU; Departments of Neurology, Multiple Sclerosis, Myelin Disorders, and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
  • Chen J; Departments of Neurology, Multiple Sclerosis, Myelin Disorders, and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
  • Paul F; Departments of Neurology, Multiple Sclerosis, Myelin Disorders, and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
  • Havla J; Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Ann Neurol ; 92(3): 476-485, 2022 09.
Article em En | MEDLINE | ID: mdl-35703428
ABSTRACT

OBJECTIVE:

Patients with myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro-axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON-independent retinal atrophy can be detected in MOGAD.

METHODS:

Eighty patients with MOGAD and 139 healthy controls (HCs) were included. OCT data was acquired with (1) Spectralis spectral domain OCT (MOGAD N = 66 and HCs N = 103) and (2) Cirrus high-definition OCT (MOGAD N = 14 and HCs N = 36). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) were quantified.

RESULTS:

At baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD-ON) compared with MOGAD eyes without a history of ON (MOGAD-NON) and HCs (p < 0.001). MOGAD-NON eyes had lower GCIPL volume compared to HCs (p < 0.001) in the Spectralis, but not in the Cirrus cohort. Longitudinally (follow-up up to 3 years), MOGAD-ON with ON within the last 6-12 months before baseline exhibited greater pRNFL thinning than MOGAD-ON with an ON greater than 12 months ago (p < 0.001). The overall MOGAD cohort did not exhibit faster GCIPL thinning compared with the HC cohort.

INTERPRETATION:

Our study suggests the absence of attack-independent retinal damage in patients with MOGAD. Yet, ongoing neuroaxonal damage or edema resolution seems to occur for up to 12 months after ON, which is longer than what has been reported with other ON forms. These findings support that the pathomechanisms underlying optic nerve involvement and the evolution of OCT retinal changes after ON is distinct in patients with MOGAD. ANN NEUROL 2022;92476-485.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Degeneração Retiniana / Neurite Óptica / Glicoproteína Mielina-Oligodendrócito / Síndromes de Imunodeficiência Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Degeneração Retiniana / Neurite Óptica / Glicoproteína Mielina-Oligodendrócito / Síndromes de Imunodeficiência Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article